- Home
- OPP vs IKT Comparison
OPP vs IKT Comparison
Compare OPP & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPP | IKT |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 220.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPP | IKT |
|---|---|---|
| Price | $7.65 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 75.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.47 | $1.33 |
| 52 Week High | $8.77 | $2.36 |
Technical Indicators
Market Signals| Indicator | OPP | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 74.20 |
| Support Level | $7.50 | $1.63 |
| Resistance Level | $7.76 | N/A |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 31.21 | 77.50 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.